Dr. John Campbell - Ivermectin in Africa and Brazil • myMedicalFreedom.org

Share to the world...

Source Link: https://www.youtube.com/watch?v=Gz4adJXLHgA

2.28M subscribers

Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching (Brazil) https://www.cureus.com/articles/82162… Background Ivermectin has demonstrated different mechanisms of action, coronavirus infection and COVID-19-related comorbidities. Prophylaxis combined with the known safety profile of ivermectin Study to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates. Prospective, July 2020 and December 2020 Inviting the entire population of Itajaí to a medical visit to enroll in the program, ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day. Study analysis consisted of comparing ivermectin users with non-users using cohorts Results 223,128 citizens of Itajaí considered 159,561 included in the analysis 113,845 (71.3%) regular ivermectin users 45,716 (23.3%) non-users Of these 4,311 ivermectin users were infected, (3.7% infection rate) 3,034 non-users (6.6% infection rate) A 44% reduction in COVID-19 infection rate Risk ratio (RR), 0.56 The regular use of ivermectin led to a 68% reduction in COVID-19 mortality Deaths 25 (0.8%) deaths in the ivermectin group 79 (2.6%) among ivermectin non-users RR, 0.32 p less than 0.0001 When adjusted for residual variables, reduction in mortality rate was 70% There was a 56% reduction in hospitalization rate 44 in the ivermectin group 99 in non ivermectin users After adjustment for residual variables, reduction in hospitalization rate was 67% p less than 0.0001 Conclusion In this large study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.

Share to the world...